
Opinion|Videos|January 5, 2026
Use of Xanomeline/Trospium in Clinical Practice
Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.
Advertisement
Episodes in this series

Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled with traditional therapies. They share early observations of improved engagement and cognitive clarity.
Panelists discuss how appropriate patient selection, titration, and adverse effect monitoring are key to maximizing outcomes.
Panelists discuss how broad adoption depends on payer coverage and growing real-world data validating long-term safety and effectiveness.
Advertisement
Related to this article

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Who Recommends COVID-19 Vaccines Without ACIP?
5

